

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nuobikan Artificial Intelligence Technology (Chengdu) Co., Ltd.

諾比侃人工智能科技(成都)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2635)

**CLARIFICATION ANNOUNCEMENT IN RELATION TO
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

Reference is made to the circular of Nuobikan Artificial Intelligence Technology (Chengdu) Co., Ltd. (the “**Company**”) dated February 23, 2026 (the “**Circular**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Company hereby announces the following clarification in relation to the biography of Mr. Wang Huan (“**Mr. Wang**”) as stated in the Circular:

Save as disclosed in the Circular, since December 12, 2025, Mr. Wang has been serving as an independent non-executive Director of 160 Health International Limited, the shares of which are listed on the main board of the Stock Exchange (stock code: 2656).

Save for the above clarification, all other information set out in the Circular remains unchanged.

By order of the Board
Nuobikan Artificial Intelligence Technology (Chengdu) Co., Ltd.
Mr. Liao Yu
Chairman and Executive Director

Hong Kong, April 8, 2026

As at the date of this announcement, the Board comprises Mr. Liao Yu, Mr. Tang Taike, Mr. Liu Bo and Ms. Wang Li as executive Directors; Mr. Ruan Jianping and Mr. Hua Zhangrong as non-executive Directors; and Ms. Cao Xiaoxue, Mr. Sang Yongsheng, Mr. Bau Siu Fung and Mr. Wang Huan as independent non-executive Directors.